Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory multiple myeloma

被引：0
|
作者：
Chauhan, D
Catley, L
Li, G
Hideshima, T
Richardson, P
Palladino, M
Anderson, KC
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Nereus Pharmaceut, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：222S / 222S
页数：1
相关论文
共 50 条
  • [41] Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
    Fostier, Karel
    De Becker, Ann
    Schots, Rik
    ONCOTARGETS AND THERAPY, 2012, 5 : 237 - 244
  • [42] Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
    Boccadoro, Mario
    Morgan, Gareth
    Cavenagh, Jamie
    CANCER CELL INTERNATIONAL, 2005, 5 (1)
  • [43] Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
    Mario Boccadoro
    Gareth Morgan
    Jamie Cavenagh
    Cancer Cell International, 5
  • [44] A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies
    Li, Eric Wenlong
    Jones, Esther
    Bryant, Christian
    King, Tracy
    Talaulikar, Dipti
    Ng, Jun Yen
    Bryant, Adam
    Ridha, Zainab
    Doo, Nicole Wong
    Menzies, Anna
    Ling, Silvia
    Ho, Shir Jing
    Abadir, Edward
    Vanguru, Vinay
    Joshua, Douglas
    Ho, P. Joy
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (04) : 521 - 529
  • [45] Proteasome inhibition: Novel therapy for multiple myeloma
    Kaufman, JL
    Lonial, S
    ONKOLOGIE, 2006, 29 (04): : 162 - 168
  • [46] Novel proteasome inhibitors as therapy in multiple myeloma
    Chauhan, D.
    Hideshima, T.
    Mitsiades, C.
    Richardson, F.
    Munshi, N.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 25 - 26
  • [47] Evaluation of gemcitabine in relapsed or refractory multiple myeloma.
    Leleu, X
    Troncy, J
    Micol, JB
    Bouafia, F
    Guieze, R
    Yakoub-Agha, I
    Depil, S
    Kuhnovski, F
    Terriou, L
    Michallet, M
    Facon, T
    Dumontet, C
    BLOOD, 2003, 102 (11) : 384B - 384B
  • [48] An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma
    Avigan, Zachary M.
    Rattu, Mohammad A.
    Richter, Joshua
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (03) : 221 - 228
  • [49] Preclinical evalution of the orally active proteasome inhibitor MLN9708 in preclinical models of human cancer
    Kupperman, Erik
    Berger, Allison
    Yu, Li
    Tsu, Christopher
    Frank, Bruzzese
    Liu, Jane
    Blank, Jonathan
    Larry, Dick
    Paul, Fleming
    Cao Yueying
    Bannerman, Bret
    Fitzgerald, Mike
    Zhang, Julie
    Yu, Jie
    Hales, Paul
    Manfredi, Mark
    Bolen, Joe
    Rolfe, Mark
    CANCER RESEARCH, 2009, 69
  • [50] Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable proteasome inhibitor-based therapy in patients with relapsed/refractory multiple myeloma
    Sasaki, Makoto
    Suzuki, Kenshi
    Abe, Yu
    Ito, Shigeki
    Nishiwaki, Kaichi
    Handa, Hiroshi
    Chou, Takaaki
    Soeda, Junpei
    Mori, Ikuo
    Shinozaki, Tomohiro
    Takezako, Naoki
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S187 - S188
12345